|
CA2375259C
(en)
|
1999-06-21 |
2009-04-28 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
|
DE10204462A1
(de)
*
|
2002-02-05 |
2003-08-07 |
Boehringer Ingelheim Pharma |
Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
US20040044014A1
(en)
|
2002-04-19 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
|
|
DE10221018A1
(de)
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
|
PE20040945A1
(es)
*
|
2003-02-05 |
2004-12-14 |
Warner Lambert Co |
Preparacion de quinazolinas substituidas
|
|
DE10307165A1
(de)
*
|
2003-02-20 |
2004-09-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
|
|
US7223749B2
(en)
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
DE10334226A1
(de)
*
|
2003-07-28 |
2005-02-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
|
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
|
MXPA06002964A
(es)
|
2003-09-16 |
2006-06-14 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores de cinasa de tirosina.
|
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
|
DE10349113A1
(de)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
|
NZ550796A
(en)
*
|
2004-05-06 |
2010-07-30 |
Warner Lambert Co |
4-phenylamino-quinazolin-6-yl-amides
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
WO2006081741A1
(en)
*
|
2005-02-05 |
2006-08-10 |
Piaoyang Sun |
Quinazoline compounds or their medical salts and preparation and medical usage thereof
|
|
KR100832594B1
(ko)
*
|
2005-11-08 |
2008-05-27 |
한미약품 주식회사 |
다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
|
|
JP5688877B2
(ja)
|
2005-11-11 |
2015-03-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌疾患の治療用キナゾリン誘導体
|
|
SI1948180T1
(sl)
|
2005-11-11 |
2013-06-28 |
Boehringer Ingelheim International Gmbh |
Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
|
|
EP1981863B1
(en)
|
2006-01-26 |
2012-10-10 |
Boehringer Ingelheim International GmbH |
Process for preparing aminocrotonylamino-substituted quinazoline derivatives
|
|
DK2068880T3
(da)
|
2006-09-18 |
2012-07-23 |
Boehringer Ingelheim Int |
Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
EA200901041A1
(ru)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
|
JP5336516B2
(ja)
|
2008-02-07 |
2013-11-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
|
|
BRPI0912170A2
(pt)
|
2008-05-13 |
2015-10-13 |
Astrazeneca Ab |
composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
|
|
UY31867A
(es)
|
2008-06-06 |
2010-01-29 |
Boehringer Ingelheim Int |
Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
|
|
US8426430B2
(en)
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
WO2010054285A2
(en)
|
2008-11-10 |
2010-05-14 |
National Health Research Institutes |
Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
|
|
EP2387401A1
(en)
|
2009-01-14 |
2011-11-23 |
Boehringer Ingelheim International GmbH |
Method for treating colorectal cancer
|
|
EP4684831A3
(en)
|
2009-02-13 |
2026-03-11 |
Boehringer Ingelheim International GmbH |
Sglt2 inhibitor for improving glycemic control
|
|
WO2010130758A1
(en)
*
|
2009-05-14 |
2010-11-18 |
Boehringer Ingelheim International Gmbh |
New combination therapy in treatment of cancer and fibrotic diseases
|
|
EP2429520A1
(en)
|
2009-05-14 |
2012-03-21 |
Boehringer Ingelheim International GmbH |
New combination therapy in treatment of oncological and fibrotic diseases
|
|
HUE044629T2
(hu)
|
2009-07-06 |
2019-11-28 |
Boehringer Ingelheim Int |
Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
|
|
US20130012465A1
(en)
|
2009-12-07 |
2013-01-10 |
Boehringer Ingelheim International Gmbh |
Bibw 2992 for use in the treatment of triple negative breast cancer
|
|
WO2011084796A2
(en)
*
|
2009-12-21 |
2011-07-14 |
Qiang Zhang |
Novel quinazoline derivatives
|
|
US20120107304A1
(en)
|
2010-04-27 |
2012-05-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy in treatment of oncological and fibrotic diseases
|
|
PT2608792T
(pt)
|
2010-08-26 |
2018-01-15 |
Boehringer Ingelheim Int |
Métodos de administração de um inibidor de egfr
|
|
EA024026B1
(ru)
*
|
2010-11-25 |
2016-08-31 |
Рациофарм Гмбх |
Новые соли и полиморфные формы афатиниба
|
|
AU2012225693A1
(en)
|
2011-03-04 |
2013-09-19 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compound and methods of use
|
|
US8828391B2
(en)
|
2011-05-17 |
2014-09-09 |
Boehringer Ingelheim International Gmbh |
Method for EGFR directed combination treatment of non-small cell lung cancer
|
|
WO2012155339A1
(zh)
|
2011-05-17 |
2012-11-22 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
|
CN102838590B
(zh)
*
|
2011-06-21 |
2014-07-09 |
苏州迈泰生物技术有限公司 |
氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
|
|
EP2753616A1
(en)
|
2011-10-06 |
2014-07-16 |
Ratiopharm GmbH |
Crystalline forms of afatinib di-maleate
|
|
CN103073539B
(zh)
*
|
2011-10-26 |
2016-05-11 |
齐鲁制药有限公司 |
4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
|
|
TWI532727B
(zh)
|
2012-01-17 |
2016-05-11 |
安斯泰來製藥股份有限公司 |
吡羧醯胺化合物
|
|
CN103772380A
(zh)
*
|
2012-10-23 |
2014-05-07 |
杨子娇 |
一类治疗房角狭窄的化合物及其用途
|
|
US20150368230A1
(en)
|
2013-02-01 |
2015-12-24 |
Boehringer Ingelheim International Gmbh |
Radiolabeled quinazoline derivatives
|
|
TR201901110T4
(tr)
|
2013-04-05 |
2019-02-21 |
Boehringer Ingelheim Int |
Empagliflozinin terapötik kullanımları.
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
HK1215378A1
(zh)
|
2013-04-18 |
2016-08-26 |
勃林格殷格翰国际有限公司 |
药物组合物、治疗方法及其用途
|
|
WO2014180271A1
(zh)
*
|
2013-05-10 |
2014-11-13 |
苏州明锐医药科技有限公司 |
阿法替尼及其中间体的制备方法
|
|
CN103254183B
(zh)
*
|
2013-05-10 |
2015-11-11 |
苏州明锐医药科技有限公司 |
阿法替尼的制备方法
|
|
CN103254182A
(zh)
*
|
2013-05-10 |
2013-08-21 |
苏州明锐医药科技有限公司 |
一种阿法替尼的制备方法
|
|
CN103242303B
(zh)
*
|
2013-05-16 |
2015-03-25 |
苏州明锐医药科技有限公司 |
阿法替尼的制备方法
|
|
WO2014183560A1
(zh)
*
|
2013-05-16 |
2014-11-20 |
苏州明锐医药科技有限公司 |
阿法替尼及其中间体的制备方法
|
|
CN104513229A
(zh)
*
|
2013-09-28 |
2015-04-15 |
正大天晴药业集团股份有限公司 |
喹唑啉衍生物及其制备方法
|
|
CN103755688B
(zh)
*
|
2013-12-24 |
2015-11-18 |
江苏奥赛康药业股份有限公司 |
一种阿法替尼化合物的制备方法
|
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
EP3089976B1
(en)
|
2014-01-02 |
2019-08-14 |
Teva Pharmaceuticals International GmbH |
Crystalline forms of afatinib dimaleate
|
|
CN105315263B
(zh)
*
|
2014-07-30 |
2018-11-27 |
正大天晴药业集团股份有限公司 |
阿法替尼中间体的合成方法
|
|
EP3023421A1
(en)
|
2014-11-21 |
2016-05-25 |
Sandoz Ag |
Crystalline forms of afatinib dimaleate
|
|
CN105801568B
(zh)
|
2015-01-15 |
2019-07-30 |
杭州普晒医药科技有限公司 |
阿法替尼一马来酸盐晶型及其制备方法和药物组合物
|
|
RU2720810C2
(ru)
*
|
2015-03-20 |
2020-05-13 |
Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. |
Соли производного хиназолина и способ их получения
|
|
CN105175400B
(zh)
*
|
2015-09-29 |
2018-04-10 |
河北神威药业有限公司 |
一种阿法替尼中间体的制备方法
|
|
WO2017141271A1
(en)
*
|
2016-02-17 |
2017-08-24 |
Sun Pharmaceutical Industries Ltd. |
Stable pharmaceutical composition of afatinib
|
|
CN106442793B
(zh)
*
|
2016-10-21 |
2019-05-24 |
河北神威药业有限公司 |
一种制备阿法替尼的中间体及其对映异构体的检测方法
|
|
AU2017357589B2
(en)
|
2016-11-10 |
2023-05-11 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
TWI808958B
(zh)
|
2017-01-25 |
2023-07-21 |
美商特普醫葯公司 |
涉及二芳基巨環化合物之組合療法
|
|
EP3727387A4
(en)
*
|
2017-12-18 |
2021-12-15 |
Sterngreene, Inc. |
PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
|
|
CN110437163A
(zh)
*
|
2018-05-03 |
2019-11-12 |
斯特恩格林公司 |
作为酪氨酸激酶抑制剂的嘧啶类化合物
|
|
WO2020068867A1
(en)
|
2018-09-25 |
2020-04-02 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
|
CN109265449B
(zh)
*
|
2018-11-07 |
2021-11-23 |
沈阳工业大学 |
Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
|
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
CN109824657A
(zh)
*
|
2019-03-26 |
2019-05-31 |
石药集团中奇制药技术（石家庄）有限公司 |
一种二马来酸阿法替尼新晶型及其制备方法和应用
|
|
WO2021030711A1
(en)
|
2019-08-15 |
2021-02-18 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
|
CN110590682A
(zh)
*
|
2019-10-14 |
2019-12-20 |
重庆医科大学 |
一种制备阿法替尼杂质的方法以及制备的杂质
|
|
WO2021094379A1
(en)
|
2019-11-12 |
2021-05-20 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
CA3166980A1
(en)
|
2020-01-20 |
2021-07-29 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
US20210369709A1
(en)
|
2020-05-27 |
2021-12-02 |
Astrazeneca Ab |
EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
|
|
WO2023051687A1
(zh)
*
|
2021-09-30 |
2023-04-06 |
北京赛特明强医药科技有限公司 |
一种喹唑啉类化合物、组合物及其应用
|
|
CN119278041A
(zh)
|
2022-03-31 |
2025-01-07 |
阿斯利康(瑞典)有限公司 |
用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂
|
|
US20240116926A1
(en)
|
2022-04-28 |
2024-04-11 |
Astrazeneca Ab |
Heteroaromatic compounds
|
|
WO2023209090A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds and their application in the treatment of cancer
|
|
AU2023262556A1
(en)
|
2022-04-28 |
2024-12-05 |
Astrazeneca Ab |
Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
|
|
WO2023209088A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds and their use in the treatment of cancer
|
|
MA71241A
(fr)
|
2022-06-27 |
2025-04-30 |
Astrazeneca Ab |
Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer
|